Related Experiment Video
Updated: Aug 26, 2026

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology
Published on: February 7, 2015
[Levosimendan. Clinical indications of a new vasoactive substance]
J-P Braun1, U Döpfmer, M Kastrup
1Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Charité, Berlin. jan.braun@charite.de
Abstract:
Levosimendan is a recently developed drug which is not yet approved for clinical routine use in Germany. The clinical use is limited to a few selected cases and it has been used as a salvage therapy in patients with severe heart insufficiency. As a potent inodilator it has been given to patients with severe heart failure, when all other therapeutic options have failed. However, in some European countries levosimendan is used in clinical routine situations and the European Society of Cardiologists has included the drug in their guidelines for treatment of acute heart failure. The following article describes the main pharmacological characteristics of levosimendan and summarises the indications for this new drug for physicians working in the field of anaesthesia or intensive care.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
